XOMA royalty-2c.png
XOMA Royalty Declares Quarterly Preferred Stock Dividends
19. Dezember 2024 07:30 ET | XOMA Royalty Corporation
XOMA Royalty January 2025 Dividend Record and Payment Dates
XOMA royalty-2c.png
XOMA Royalty Significantly Expands its Royalty and Milestone Portfolio with the Addition of Over 60 Early-Stage Programs from Twist Bioscience
22. Oktober 2024 08:00 ET | XOMA Corporation
XOMA Royalty acquires 50% economic interest in portfolio of 60-plus early-stage assets with $15M payment to Twist Bioscience
XOMA royalty-2c.png
XOMA Declares Quarterly Preferred Stock Dividends
20. Juni 2024 07:30 ET | XOMA Corporation
July 2024 Dividends
XOMA royalty-2c.png
XOMA Corporation Announces Closing of Tender Offer
03. April 2024 09:00 ET | XOMA Corporation
XOMA completes acquisition of Kinnate.
XOMA royalty-2c.png
XOMA Enters into Agreement to Acquire Kinnate Biopharma for Between $2.3352 and $2.5879 in Cash Per Share Plus a Contingent Value Right
16. Februar 2024 08:00 ET | XOMA Corporation
XOMA enters agreement to acquire Kinnate for cash and CVR; Expects to add $9.5M cash to balance sheet upon completion of acquisition
XOMA royalty-2c.png
FDA Acceptance of Zevra’s Arimoclomol NDA Filing for Niemann-Pick Disease Type C (NPC) Results in XOMA Making a $1 Million Milestone Payment to LadRx
11. Januar 2024 16:05 ET | XOMA Corporation
EMERYVILLE, Calif., Jan. 11, 2024 (GLOBE NEWSWIRE) -- XOMA Corporation (NASDAQ: XOMA), the biotech royalty aggregator, announced today that based upon the U.S. Food and Drug Administration’s (FDA)...
XOMA royalty-2c.png
XOMA Declares Quarterly Preferred Stock Dividends
20. Dezember 2023 07:30 ET | XOMA Corporation
January quarterly dividend payment to XOMAP and XOMAO stockholders of record on 1/3/2024
XOMA royalty-2c.png
XOMA Acquires Cashflow-Generating Asset for its Royalty and Milestone Portfolio
30. März 2023 07:30 ET | XOMA Corporation
EMERYVILLE, Calif., March 30, 2023 (GLOBE NEWSWIRE) -- XOMA Corporation (NASDAQ: XOMA), announced today it has acquired the commercial payment and a portion of the milestone rights to IXINITY®...